Dr. Daver Discusses Single-Agent Immunotherapy in AML – OncLive
|
Dr. Daver Discusses Single-Agent Immunotherapy in AML
OncLive Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses single-agent immunotherapy in acute myeloid leukemia (AML). Although single agent PD-1 inhibition … |
